Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade in Waldenstrom's Macroglobulinemia
NCT00142129Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2003
- Primary completion
- Jun 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate. Started Dec 2003; status: completed.
02
Drugs
bortezomib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00142129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142129.